SCHEMBL9583019

SCHEMBL9583019

CCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC)OCn1cnc2c(N)nc(Cl)nc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 2/20 0.42
▸ HDAC2 Q92769 2/20 0.42
▸ PDE3A Q14432 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ PDE8A O60658 4/20 0.39
▸ CYP3A4 P08684 4/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ VCP P55072 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ EP300 Q09472 1/20 0.39
▸ PRKCA P17252 2/20 0.38
▸ PRKCE Q02156 1/20 0.38
▸ PRKCQ Q04759 1/20 0.38
▸ PRKCD Q05655 1/20 0.38
▸ CDK1 P06493 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9584540 1.00 HDAC1 (0.42) HDAC1HDAC2PDE3AALDH1A1LMNA
SCHEMBL9583468 0.95 PDE3A (0.47) HDAC1HDAC2PDE3AALDH1A1LMNA
SCHEMBL9583536 0.90 CDK1 (0.46) PDE3AALDH1A1LMNACYP3A4MEN1
SCHEMBL9583245 0.90 CDK1 (0.46) PDE3AALDH1A1LMNACYP3A4MEN1
SCHEMBL9583142 0.90 CDK1 (0.46) PDE3AALDH1A1LMNACYP3A4MEN1
SCHEMBL9583458 0.90 CDK1 (0.46) PDE3AALDH1A1LMNACYP3A4MEN1
SCHEMBL9583697 0.88 HDAC6 (0.42) HDAC1HDAC2PDE3AALDH1A1LMNA
SCHEMBL9583048 0.87 PDE3A (0.40) PDE3AALDH1A1LMNACYP3A4MEN1
SCHEMBL9583144 0.87 PDE3A (0.40) PDE3AALDH1A1LMNACYP3A4MEN1
SCHEMBL9583789 0.87 HDAC1 (0.49) HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5250535-A Herpes virus; nontoxic; side effect reduction; humans and veterinary medicine SYNTEX INC. (US) 1993-10-05 — — US disclosed
US-4803271-A Process for preparing guanine derivatives SYNTEX (U.S.A.) INC. (US) 1989-02-07 — — US disclosed
US-4612314-A Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines as antiviral agent SYNTEX (U.S.A.) INC. (US) 1986-09-16 — — US disclosed
EP-0085424-A2 Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines as antiviral agent SYNTEX (U.S.A.) INC. (US) 1983-08-10 — — EP disclosed
Send feedback